argenx's acquisition of Forte Biosciences adds a first-in-class anti-CD122 antibody to its immunology pipeline, expanding its therapeutic offerings
Executive summary: argenx agreed to acquire Forte Biosciences to obtain the first-in-class anti-CD122 antibody FB102. The acquisition adds a novel IL-2 pathway inhibitor to argenx's pipeline, potentially creating differentiated treatments for autoimmune disorders and strengthening its competitive position.
Who is involved: argenx (Belgium‑based biotech), Forte Biosciences (US biotech), and the FB102 antibody asset.
Likely next: Completion of the acquisition is pending antitrust clearance; post‑close, argenx plans to integrate FB102 into clinical development with a Phase I trial expected in mid‑2027.
argenx announced a definitive agreement to acquire Forte Biosciences, gaining control of the FB102 antibody that targets the IL-2 pathway via CD122. The deal expands argenx's immunology portfolio with a novel mechanism that could address autoimmune diseases with limited current options. The transaction underscores continued M&A activity in the biotech sector as companies seek differentiated assets.
Timeline
- — argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline (GlobeNewswire)
Analysis — what this means
Likely next events
- Regulatory clearance under Hart-Scott-Rodino expected by October 2026.
- Integration of FB102 into argenx's clinical development slated for Q1 2027.
- Potential Phase I trial of FB102 in autoimmune disease planned for mid‑2027.
- argenx may allocate up to $200 million of cash to fund the acquisition and early development.
Sectors affected
- immunology therapeutics
- biotech mergers and acquisitions
Regulatory implications
- Subject to US Hart-Scott-Rodino antitrust review; decision anticipated Q4 2026.
- European Medicines Agency will assess FB102 for orphan drug designation in 2027.
Historical parallels
- 2021: argenx acquired Zilucoplan (anti‑C5) from InflaRx for $325 million.
- 2020: Merck purchased Pandion Therapeutics for $1.85 billion to gain IL‑2 pathway assets.